The disclosure relates to the identification and the use of compounds which regulate the expression of at least one Sestrin gene, for preventing and/or attenuating skin ageing, and/or for hydrating the skin and/or for regulating skin pigmentation. The method includes the following steps: a. bringing at least one test compound in contact with a sample of human keratinocytes or melanocytes; b. measuring the expression of at least one Sestrin gene chosen from SESN3, SESN2 and SESN1 in the keratinocytes or melanocytes; c. selecting the compounds for which an activation of at least 1.6 fold of the expression of at least one of the genes is measured in the keratinocytes treated in a. compared with the untreated keratinocytes, or for which a significant modulation of the expression of at least one of the genes is measured in the melanocytes treated in a. compared with the untreated melanocytes.

Use of Mesembryanthemum crystallinum L. callus extract in the manufacture of a medicament or a skin care product, wherein the medicament or skin care product is for at least one of delaying skin cell aging, nursing skin, repairing skin, treating skin cancer, and preventing skin cancer.

Disclosed herein are compositions and methods for acutely raising nitric oxide levels in a subject. In one example, the composition can include, an effective amount of a NOS dependent source of nitric oxide; an effective amount of a NOS independent source of nitric oxide; and an effective amount of a myeloperoxidase inhibitor; wherein the composition acutely raises nitric oxide levels in a subject above a level provided by the available sources of nitric oxide in the subject prior to administration of the composition. Further presented is a method of treating a subject for a condition or disorder that is response to nitric oxide therapy, including: acutely raising nitric oxide levels in a subject by simultaneously increasing biosynthesis of nitric oxide, increasing nitrate/nitrite levels, and inhibiting myeloperoxidase activity.

A cosmetic or dermatological composition which comprises carnitine, a precursor thereof, a metabolite thereof and/or a derivative thereof.

The present invention relates to a method of cultivating stem/progenitor cells of the amniotic membrane of umbilical cord that comprises obtaining a tissue explant from the amniotic membrane of umbilical cord and cultivating the tissue explant in suitable cultivation media and cultivation conditions over a suitable period of time. The method may include isolating the stem/progenitor cells from the tissue cultures. The stem cells may be epithelial or mesenchymal stem/progenitor cells. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes.

The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles) and for treating the loss of skin suppleness. A preferred composition, particularly adapted for eye contour, comprises the Albizia Julibrissin extract combined with Darutoside that can be extracted from Siegesbeckia Orientalis.

Synergistic nutraceutical or pharmaceutical anti-inflammatory compositions include a therapeutically effective combination of: an extract selectively enriched in 3-O-acetyl-11-keto-β-boswellic acid (AKBA) derived from Boswellia serrata; and a Boswellia serrata non-acidic resin extract (BNRE). The compositions can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, and/or endothelial dysfunction. The invention further discloses the amelioration of pro-inflammatory biomarker proteins or molecules, whose expression/production is altered during inflammatory diseases.

The present disclosure is directed to dermatological formulations and their use for treating a variety of dermatological diseases and disorders, and for repairing and restoring a disrupted epidermal barrier, inhibiting inflammation, restoring a proper environment for maintaining a balanced symbiotic microbiome, and inhibiting the growth of pathogenic microorganisms in the epidermis—the outer layer of mammalian skin.

A pressure support system that comprises a patient circuit, a docking assembly, and a tank. The patient circuit delivers a pressurized flow of breathable gas to a patient. The docking assembly has an inlet and an outlet that is adapted to receive the pressurized flow of breathable gas, and is also adapted to be connected with the patient circuit. The tank is constructed and arranged to be removably connected with the docking assembly, and enables the pressurized flow of breathable gas to pass therethrough. The tank is also adapted to contain a liquid such that a humidity level of the pressurized flow of breathable gas is elevated as the pressurized flow of breathable gas passes therethrough.

SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.